Published in Lab Law Weekly, June 10th, 2005
For the quarter ended March 31, 2005, the company reported a net loss of $6.8 million (or $0.35 per share), compared to a net loss of $5.9 million (or $0.31 per share) in the first quarter of 2004.
Research and development expenses for the first quarter of 2005 totaled $5.3 million, compared to $4.7 million in the first quarter of 2004. The increase in research and development expenses in the first quarter of 2005 was due mainly to the growth in the company's laboratory operations, preclinical activities and personnel associated with advancing the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.